Abstract Objectives To prospectively evaluate oncological control, pathological progression, and its predictors following focal low‐dose‐rate (LDR) brachytherapy for low‐intermediate risk prostate cancer (PCa). Patients and methods LIBERATE is a prospective, multi‐centre clinical registry of patients who have undergone focal LDR brachytherapy for low‐intermediate risk PCa since September 2019 (ACTRN:12619001669189). Unifocal ISUP GG1 (≥10 mm in ≥1 core), GG2 (any length) or GG3 (longest core0.55 ng/mL/year was a strong predictor of pathological progression (OR 23.54, 95% CI 4.28–129.35, p = 0.001), with a sensitivity of 76.9% and specificity of 90.5%. Conclusion With a median follow‐up of 38 months, these early results suggest that focal LDR brachytherapy for low‐intermediate risk, single‐lesion, imaging‐visible PCa demonstrates satisfactory oncological control. However, further follow‐up is needed to assess long‐term oncological outcomes.
Adhami et al. (2026) studied this question.